News

Tuesday
November, 5

China-plus-1 benefits drug companies: Biocon MD

Featured in:



BENGALURU: Biocon MD & CEO Siddharth Mittal said the China-plus-one strategy of many global companies augurs well for Indian pharma players. The strategy, he said, will benefit the company’s subsidiary Syngene on the research side, and benefit Biocon from a procurement side. “The existing customers, on the dedicated centres side, are expanding their workforce in India with Syngene. Some have moved their resources from China,” he said.

Mittal said more outsourcing is moving to the East because customers don’t want to pause their development pipeline and want to optimise their cash resources. “They see outsourcing as an advantage,” he said. Biocon’s revenue rose 59% to Rs 3,516 crore in the June quarter.





Source link

Find us on

Latest articles

- Advertisement - spot_imgspot_img

Related articles

A Strong Presence of the German Economy in the...

A Strong Presence of the German Economy in the Entire Asia-Pacific Region is a Decisive Factor for...

Maharashtra Govt Approves $10 Billion Proposal By Israel’s Tower...

Maharashtra Govt Approves $10 Billion Proposal By Israel's Tower Semiconductor And Adani Group To Set Up Chip...

Rosler & AM Solutions To Showcase Advanced Finishing Technologies...

RÖSLER & AM SOLUTIONS TO SHOWCASE ADVANCED FINISHING TECHNOLOGIES AT MEDICAL TECHNOLOGY IRELAND 2024 Rösler Group and its...

New PA6 and UHMWPE Compound Optimizes Bridge Bearing Properties

Better than PTFE and UHMWPE: New PA6 and UHMWPE Compound Optimizes Bridge Bearing Properties   MKSM, a new bridge...

The Number Of Bitcoin Millionaires Has Soared 111% In...

The Number Of Bitcoin Millionaires Has Soared 111% In The Last Year As The Cryptocurrency Rallies The number...

3DPRINTUK CELEBRATES THE LAUNCH OF THE FIRST COMMERCIALLY AVAILABLE...

3DPRINTUK CELEBRATES THE LAUNCH OF THE FIRST COMMERCIALLY AVAILABLE SAF MACHINE IN THE UK WITH FREE 3D...